

# Next Generation Sequencing for Minimal Residual Disease Detection

MEDICAL POLICY NUMBER: 110

<b>Effective Date:</b> 4/1/2023	COVERAGE CRITERIA .....	2
<b>Last Review Date:</b> 3/2023	POLICY CROSS REFERENCES.....	2
<b>Next Annual Review:</b> 6/2023	POLICY GUIDELINES.....	3
	REGULATORY STATUS.....	4
	CLINICAL EVIDENCE AND LITERATURE REVIEW .....	4
	MEDICARE ADVANTAGE .....	<b>Error! Bookmark not defined.</b>
	BILLING GUIDELINES AND CODING .....	7
	REFERENCES.....	8
	POLICY REVISION HISTORY.....	9
	APPENDICES.....	<b>Error! Bookmark not defined.</b>

**INSTRUCTIONS FOR USE:** Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

**SCOPE:** Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

## PLAN PRODUCT AND BENEFIT APPLICATION

Commercial

Medicaid/OHP\*

Medicare\*\*

### \*Medicaid/OHP Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

### \*\*Medicare Members

This *Company* policy may be applied to Medicare Plan members only when directed by a separate *Medicare* policy. Note that investigational services are considered “**not medically necessary**” for Medicare members.

## COVERAGE CRITERIA

**Note:** This policy only addresses the use of next generation sequencing (NGS) for minimal residual disease (MRD) detection. Other MRD techniques (e.g., flow cytometry, polymerase chain reaction) are not addressed in this policy and may be considered medically necessary.

### *Lymphoid Malignancies*

- I. Minimal residual disease detection in lymphoid malignancies using next-generation sequencing (e.g., ClonoSeq) may be considered **medically necessary** for the treatment of acute lymphocytic leukemia, chronic lymphocytic leukemia, or multiple myeloma.
- II. Minimal residual disease detection in lymphoid malignancies using next-generation sequencing (e.g., ClonoSeq) is considered **investigational** when criterion I. above is not met.

### *Solid Tumors*

- III. Minimal residual disease detection in solid tumors using next-generation sequencing (e.g., Signatera, Guardant Reveal) is considered **investigational**.

Link to [Evidence Summary](#)

## POLICY CROSS REFERENCES

- [Circulating Tumor Cell and DNA Assays for Cancer Management](#), MP122

The full Company portfolio of current Medical Policies is available online and can be [accessed here](#).

## **POLICY GUIDELINES**

### **BACKGROUND**

#### Minimal Residual Disease

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body following treatment. To test for MRD, samples are drawn from either the patient's blood or bone marrow aspiration. MRD testing is used to determine cancer treatment's efficacy, predict risk of relapse and guide subsequent treatment. The most common tests used to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).<sup>1</sup>

#### Next Generation Sequencing

Next generation sequencing (NGS) is a form of MRD that rapidly examines stretches of DNA or RNA that purports to accurately detect very small amounts of malignant cells and other genetic abnormalities. The U.S. Food and Drug Administration approved ClonoSeq to detect MRD in B-cell acute lymphoblastic leukemia (ALL) and myeloma.<sup>1</sup>

#### ClonoSeq (Adaptive Biotechnologies)

The ClonoSeq assay is an *in vitro* diagnostic assay that uses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify the frequency and distribution of clonal sequences consistent with a malignant lymphocyte in bone marrow samples. The Assay measures minimal residual disease (MRD) to monitor changes in burden of disease during and after treatment. An initial assay determines the presence of 1 or more dominant sequences and subsequent sample assays allow tracking of the dominant sequence(s).<sup>2</sup>

#### Signatera (Natera, Inc.)

Signatera is a blood-based liquid biopsy test that analyzes cell-free, circulating tumor DNA (ctDNA) using next-generation sequencing to detect 16 cancer-associated single-nucleotide variants (SNVs). The test is intended to monitor for residual disease, disease recurrence, and treatment response in patients with solid tumors.<sup>3</sup>

#### Guardant Reveal (Guardant Health Inc.)

Guardant Reveal is a blood-only liquid biopsy test for residual disease and recurrence monitoring for early-stage colorectal cancer.<sup>4</sup> The assay purports to identify high-risk patients who are most likely to recur and may benefit most from adjuvant chemotherapy and active surveillance by detecting minimal residual disease.

## Lymphoid Malignancies

Lymphoid malignancies are cancers that originate from lymphocytes. Examples include multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma and lymphocytic leukemias.

## **REGULATORY STATUS**

### **U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

In September 2018, the FDA granted De Novo designation for the ClonoSeq® Minimal Residual Disease assay (Adaptive Biotechnologies®, Seattle, WA) in patients with multiple myeloma or acute lymphoblastic leukemia.

Other next generation assays that purport to detect minimal residual disease include Signatera (Natera, Inc.) and Guardant Reveal (Guardant Health Inc.) assays. As of April 2021, neither has been approved by the FDA as companion diagnostics for non-solid tumor cancer therapies.

## **CLINICAL EVIDENCE AND LITERATURE REVIEW**

### **EVIDENCE REVIEW**

#### Lymphoid Malignancies

##### *Systematic Reviews*

In 2018 (archived 2021), Hayes conducted a systematic review evaluating the analytical validity, clinical validity and clinical utility of ClonoSeq in the assessment of minimal residual disease (MRD) in lymphoid malignancies.<sup>2</sup> As of October 2018, 3 retrospective cohort studies were identified evaluating ClonoSeq's clinical validity by comparing the assay to MRD detection by multiparametric flow cytometry (MPFC), and immunoglobulin heavy chain locus (IgH) ClonoSeq. Sample sizes ranged from 32 to 108 patients. No peer-reviewed studies were identified that assessed the assay's analytical validity. While clinical validity studies reported a high to moderately high level of concordance between ClonoSeq and MPFC, Hayes concluded that the lack of clinical utility studies rendered evidence insufficient to support claims that ClonoSeq accurately measures MRD and improves patient outcomes. Moreover, studies only examined the ClonoSeq assay, and not the sequence generation and downstream data analyses that collectively constitute the ClonoSeq process. Citing "very low" quality evidence, authors ultimately assigned a "D2" rating (insufficient evidence) for the use of ClonoSeq in detecting and measuring MRD in bone marrow samples.

## *Additional Studies*

Since the Hayes review discussed above, one additional peer-reviewed study was identified.

In 2018, Perrot and colleagues conducted a post-hoc analysis of data from a recent clinical trial to assess the prognostic value of next-generation sequencing to obtain MRD measurements.<sup>5</sup> It is unclear if ClonoSeq was the next generation sequencing process utilized. In total, data from 127 patients at 50-month follow-up were reported. Authors reported that MRD was a strong prognostic factor for both progression-free survival (HR, 0.22; 95% CI 0.15-0.34;  $P < .001$ ) and overall survival (HR, 0.24; 95% confidence interval, 0.11-0.54;  $P = .001$ ). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of subsequent treatments and other baseline characteristics. However, patients with undetectable MRD also continued to show a linear risk of relapse after stopping treatment. Authors concluded that NGS-determined MRD status may be used as a prognostic biomarker in patients with multiple myeloma. The study is limited however by its retrospective design, as post-hoc correlations may be vulnerable to confounding by multiple variables. Additional studies comparing next-generation sequencing to PCR and flow cytometry are necessary to establish superiority.

## Solid Tumors

- In 2020, ECRI published a genetic test assessment evaluating the clinical validity and utility of the Signatera ctDNA test for molecular residual disease assessment and recurrence monitoring of solid tumor cancers.<sup>3</sup> In total, 4 relevant clinical validity studies were identified evaluating patients (n=4-130) with breast, colorectal and non-small cell lung cancers. Study results were limited by small sample sizes and the analysis of multiple indications. Each study acknowledged the need for additional studies to determine clinical validity and utility.<sup>6-9</sup>
- In 2020, Cullinane and colleagues published a systematic review and meta-analysis assessing the association of circulating tumor DNA with disease-free survival (DFS) in breast cancer.<sup>10</sup> Investigators systematically searched the literature through October 2019, identified eligible studies, assessed study quality, extracted data and pooled results. In total, 8 studies (n = 739) were included for review. The primary outcome was the association of ctDNA with DFS or relapse-free survival in breast cancer. Secondary outcomes focused on subgroup analysis in the setting of early breast cancer and metastatic breast cancer. Results indicated that ctDNA gene variation detection (both before and after treatment) was statistically significantly associated with shorter DFS (HR, 4.44; 95% CI, 2.29-8.61;  $P < .001$ ). Detection of ctDNA was statistically significantly associated with a reduction in DFS in both the early breast cancer subgroup (HR, 8.32; 95% CI, 3.01-22.99;  $P < .001$ ) and the metastatic or locally advanced subgroup (HR, 1.91; 95% CI, 1.35-2.71;  $P < .001$ ). Pretreatment plasma detection of ctDNA was statistically significantly associated with reduced DFS (HR, 3.30; 95% CI, 1.98-5.52;  $P < .001$ ). Posttreatment sampling of ctDNA failed to achieve statistical significance (HR, 8.17; 95% CI, 1.01-65.89;  $P = .05$ ). Investigators concluded that elevated plasma ctDNA was associated with a high risk of relapse. This finding suggests that plasma ctDNA may help stratify risk and personalize patient follow-up.

Limitations included the heterogeneity of included studies and heterogeneous techniques employed to quantify ctDNA.

- Additional systematic reviews assessing the efficacy of clinical validity and utility of ctDNA analysis for colorectal cancer patients were identified.<sup>11-13</sup> Studies reported that KRAS mutations may be considered a prognostic biomarker for colorectal cancer. Investigators called for additional, well-designed prospective studies to verify results reported to date.

## **CLINICAL PRACTICE GUIDELINES**

### National Comprehensive Cancer Network (NCCN)

- In 2022, the NCCN published guidelines (Version 1.2022) addressing the diagnosis and management of acute lymphoblastic leukemia.<sup>14</sup> Authors stated that NGS-based MRD tests based on quantification of immunoreceptor genes in patients with ALL is a “suitable” method for MRD quantification.<sup>14</sup> The guideline also noted that NGS-based assays are frequently used to detect clonal rearrangements in immunoglobulin and/or T-cell receptor genes.
- In 2022, the NCCN published guidelines (version 5.2022) addressing the diagnosis and management of multiple myeloma.<sup>15</sup> The guideline utilizes employed the International Myeloma Working Group criteria, which considers NGS a technique for MRD detection. The guidelines also recommend NGS panels on bone marrow as useful adjunct in allowing further risk categorization through the identification of additional abnormalities that may be of prognostic/or therapeutic value.
- In 2022, NCCN published guidelines (Version 2.2022) addressing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. The guidelines state, “Evidence from clinical trials suggests that undetectable MRD in the peripheral blood after the end of treatment is an important predictor of treatment efficacy... MRD evaluation should be performed using an assay with a sensitivity of  $10^{-4}$  according to the standardized ERIC method or standardized NGS method.”<sup>16</sup>
- In 2022, the NCCN published guidelines (Version 1.2022) addressing the diagnosis and management of colon cancer.<sup>17</sup> Investigators stated that “insufficient data to recommend the use of multigene assays, Immunoscore or post-surgical ctDNA to estimate risk of recurrence or determine adjuvant therapy.”<sup>17</sup>

### American Society of Clinical Oncology/Cancer Care Ontario (ASCO/CCO)

In 2019, ASCO/CCO published a clinical practice guideline evaluating the treatment of multiple myeloma.<sup>18</sup> Recommendations were made on the basis of expert opinion and a non-systematic literature review. Investigators stated that while multiple studies have reported improved outcomes among patients with MRD negative status, “there is no universal agreement as to which method is preferred, when the testing should be performed, and at what interval.”<sup>18</sup> Authors argued that “until

prospective trials have validated its use, this technology should not be used to guide treatment decisions.”<sup>18</sup>

## EVIDENCE SUMMARY

There is sufficient support from the evidence base and from clinical practice guideline organizations to consider the use of next-generation sequencing for minimal residual disease detection (MRD) in lymphoid malignancies as medically necessary. NCCN guidelines support the use of MRD testing as an essential component of management for patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). In contrast, there are not enough large, well-designed studies that assess these tests in patients with solid tumors. These studies will need to compare outcomes between patients managed with next generation assays versus patients managed with alternative tests and/or no tests. For this reason, minimal residual disease detection using next-generation sequencing may be considered medically necessary for patients with lymphoid malignancies but investigational for patients with solid tumors.

## BILLING GUIDELINES AND CODING

Clonoseq Assay (Adaptive Biotechnologies) will only pay when billed with any of the following ICD-10 codes:

### Multiple Myeloma

- C90.00 Multiple myeloma not having achieved remission
- C90.01 Multiple myeloma in remission
- C90.02 Multiple myeloma in relapse

### Acute Lymphoblastic Leukemia

- C91.00 Acute lymphoblastic leukemia not having achieved remission
- C91.01 Acute lymphoblastic leukemia, in remission
- C91.02 Acute lymphoblastic leukemia, in relapse

### Chronic Lymphocytic Leukemia

- C91.1 Chronic lymphocytic leukemia of B-Cell type
- C91.10 Chronic lymphocytic leukemia of B-Cell type not having achieved remission
- C91.11 Chronic lymphocytic leukemia of B-Cell type in remission
- C91.12 Chronic lymphocytic leukemia of B-Cell type in relapse

CODES*		
CPT	0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient-specific panel for future comparisons to evaluate for MRD

0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD
0340U	"Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and
0364U	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate
81479	Unlisted molecular pathology procedure

**\*Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- **See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.**
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as "medically unlikely edits" (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

1. Leukemia and Lymphoma Society. Minimal Residual Disease (MRD) - Fact Sheet. [https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FS35\\_MRD\\_Final\\_2019.pdf](https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FS35_MRD_Final_2019.pdf). Published 2019. Accessed 4/29/2022.
2. Hayes Inc. Molecular Test Assessment. clonoSEQ (Adaptive Biotechnologies). Archived Nov 10, 2021. <https://evidence.hayesinc.com/report/gte.clono3338>. Accessed 4/29/2022.
3. ECRI Institute. Signatera (Natera, Inc.) ctDNA Test for Molecular Residual Disease Assessment and Recurrence Monitoring of Solid Tumor Cancers. April 2022. <https://www.ecri.org/components/ECRIgene/Documents/EG0348.pdf>. Accessed 4/29/2022.
4. Guardant Health Inc. Background: Guardant Reveal™ liquid biopsy test. [https://guardantreveal.com/?utm\\_medium=ppc&utm\\_source=google&utm\\_content=General&utm\\_term=guardant%20health%20reveal&utm\\_id=PS2202172](https://guardantreveal.com/?utm_medium=ppc&utm_source=google&utm_content=General&utm_term=guardant%20health%20reveal&utm_id=PS2202172). Accessed 4/29/2022.
5. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. *Blood*. 2018;132(23):2456-2464. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284215/>.
6. Jamal-Hanjani M, Wilson GA, Horswell S, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. *Ann Oncol*. 2016;27(5):862-867
7. Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. *Clin Cancer Res*. 2019;25(14):4255-4263



8. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. *JAMA Oncol.* 2019;5(8):1124-1131
9. Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nature Cancer.* 2020;1(9):873-881. <https://doi.org/10.1038/s43018-020-0096-5>.
10. Cullinane C, Fleming C, O'Leary DP, et al. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2020;3(11):e2026921
11. Hao Y-X, Fu Q, Guo Y-Y, et al. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. *OncoTargets and therapy.* 2017;10:945
12. Perdyan A, Spsychalski P, Kacperczyk J, Rostkowska O, Kobiela J. Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis. *Crit Rev Oncol Hematol.* 2020;154:103065
13. Bach S, Sluiter NR, Beagan JJ, et al. Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. *JNCI Cancer Spectr.* 2019;3(3):pkz042
14. National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia - Version 1.2022. April 4, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/all.pdf](https://www.nccn.org/professionals/physician_gls/pdf/all.pdf). Accessed 4/28/2022.
15. National Comprehensive Cancer Network. Multiple Myeloma. Version 5.2022. March 9, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed 4/28/2022.
16. National Comprehensive Cancer Network (NCCN). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2022. January 18, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/cli.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cli.pdf). Accessed 4/29/2022.
17. National Comprehensive Cancer Network. Colon Cancer. (Version 2.2022. February 25, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed 4/29/2022.
18. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. *Journal of Clinical Oncology.* 2019;37(14):1228-1263. <https://ascopubs.org/doi/pdfdirect/10.1200/JCO.18.02096>.

## POLICY REVISION HISTORY

DATE	REVISION SUMMARY
2/2023	Converted to new policy template.
4/2023	Q2 2023 code set update